327 related articles for article (PubMed ID: 24972932)
1. Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB).
Bartelheim K; Sumerauer D; Behrends U; Kodetova D; Kucera F; Leuschner I; Neumayer P; Oyen F; Rübe C; Siebert R; Schneppenheim R; Seeringer A; Vasovcak P; Frühwald MC
Cancer Genet; 2014 Sep; 207(9):379-83. PubMed ID: 24972932
[TBL] [Abstract][Full Text] [Related]
2. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013.
Bourdeaut F; Chi SN; Frühwald MC
Cancer Genet; 2014 Sep; 207(9):346-51. PubMed ID: 25468731
[TBL] [Abstract][Full Text] [Related]
3. Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumor--feasibility and efficacy of multimodal therapy in a long-term survivor.
Seeringer A; Reinhard H; Hasselblatt M; Schneppenheim R; Siebert R; Bartelheim K; Leuschner I; Frühwald MC
Cancer Genet; 2014 Sep; 207(9):429-33. PubMed ID: 25262118
[TBL] [Abstract][Full Text] [Related]
4. Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors?
Renard C; Pissaloux D; Decouvelaere AV; Bourdeaut F; Ranchère D
Cancer Genet; 2014 Sep; 207(9):384-9. PubMed ID: 25053104
[TBL] [Abstract][Full Text] [Related]
5. Pathology and diagnosis of SMARCB1-deficient tumors.
Margol AS; Judkins AR
Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
7. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.
Hasselblatt M; Gesk S; Oyen F; Rossi S; Viscardi E; Giangaspero F; Giannini C; Judkins AR; Frühwald MC; Obser T; Schneppenheim R; Siebert R; Paulus W
Am J Surg Pathol; 2011 Jun; 35(6):933-5. PubMed ID: 21566516
[TBL] [Abstract][Full Text] [Related]
8. Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy.
Kerl K; Holsten T; Frühwald MC
Pediatr Hematol Oncol; 2013 Oct; 30(7):587-604. PubMed ID: 23848359
[TBL] [Abstract][Full Text] [Related]
9. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS).
Kordes U; Bartelheim K; Modena P; Massimino M; Biassoni V; Reinhard H; Hasselblatt M; Schneppenheim R; Frühwald MC
Pediatr Blood Cancer; 2014 May; 61(5):919-21. PubMed ID: 24123847
[TBL] [Abstract][Full Text] [Related]
10. Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome.
Frühwald MC; Hasselblatt M; Wirth S; Köhler G; Schneppenheim R; Subero JI; Siebert R; Kordes U; Jürgens H; Vormoor J
Pediatr Blood Cancer; 2006 Sep; 47(3):273-8. PubMed ID: 16206192
[TBL] [Abstract][Full Text] [Related]
11. Rhabdoid tumor predisposition syndrome.
Sredni ST; Tomita T
Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
[TBL] [Abstract][Full Text] [Related]
12. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features.
Cho YM; Choi J; Lee OJ; Lee HI; Han DJ; Ro JY
Pathol Int; 2006 Nov; 56(11):702-6. PubMed ID: 17040295
[TBL] [Abstract][Full Text] [Related]
13. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
14. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
15. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
16. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
Rizzo D; Fréneaux P; Brisse H; Louvrier C; Lequin D; Nicolas A; Ranchère D; Verkarre V; Jouvet A; Dufour C; Edan C; Stéphan JL; Orbach D; Sarnacki S; Pierron G; Parfait B; Peuchmaur M; Delattre O; Bourdeaut F
Am J Surg Pathol; 2012 Jul; 36(7):964-72. PubMed ID: 22614000
[TBL] [Abstract][Full Text] [Related]
17. Conventional chondrosarcoma in a survivor of rhabdoid tumor: enlarging the spectrum of tumors associated with SMARCB1 germline mutations.
Forest F; David A; Arrufat S; Pierron G; Ranchere-Vince D; Stephan JL; Clemenson A; Delattre O; Bourdeaut F
Am J Surg Pathol; 2012 Dec; 36(12):1892-6. PubMed ID: 23154773
[TBL] [Abstract][Full Text] [Related]
18. Congenital Disseminated Extrarenal Malignant Rhabdoid Tumor.
Boudjemaa S; Petit A; Dainese L; Bourdeaut F; Lipsett J; Coulomb A
Pediatr Dev Pathol; 2015; 18(5):401-4. PubMed ID: 25751458
[TBL] [Abstract][Full Text] [Related]
19. Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium.
Donner LR; Wainwright LM; Zhang F; Biegel JA
Hum Pathol; 2007 Jun; 38(6):935-9. PubMed ID: 17376508
[TBL] [Abstract][Full Text] [Related]
20. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.
DeCristofaro MF; Betz BL; Wang W; Weissman BE
Oncogene; 1999 Dec; 18(52):7559-65. PubMed ID: 10602515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
